Search results for " vaccines"

showing 10 items of 472 documents

Antiidiotypic DNA vaccination induces serum bactericidal activity and protection against group B meningococci

2006

No vaccine is available for preventing infections by serogroup B Neisseria meningitidis (MenB), which accounts for a major portion of meningococcal cases in developed countries, because of the poor immunogenicity of the capsular polysaccharide (CP) even after protein conjugation. We have previously induced anticapsular antibodies by immunization with a single chain variable fragment (scFv), which mimics a protective CP epitope. This surrogate antigen, however, was ineffective at inducing serum bactericidal activity, an accepted marker of protection in humans. Serum bactericidal activity was consistently achieved by immunizing mice with the scFv-encoding gene. Immunization with vectors witho…

Blood Bactericidal ActivityImmunologyImmunoglobulin Variable Regionchemical and pharmacologic phenomenaBlood Bactericidal ActivityNeisseria meningitidis Serogroup BEpitopeArticleMicrobiologyDNA vaccinationMiceAntigenserogroup B Neisseria meningitidis; single chain variable fragment; DNA vaccinationChlorocebus aethiopsVaccines DNAImmunology and AllergyAnimalsRats WistarMice Inbred BALB CbiologyImmunogenicityArticlesVirologyAntibodies BacterialRatsBacterial vaccineMeningococcal InfectionsImmunizationAnimals NewbornBacterial VaccinesCOS Cellsbiology.proteinAntibody
researchProduct

Synthetic Antitumor Vaccines from Tetanus Toxoid Conjugates of MUC1 Glycopeptides with the Thomsen-Friedenreich Antigen and a Fluorine-Substituted An…

2010

Breast NeoplasmsCancer VaccinesAntibodiesCatalysisMiceCell Line TumorTetanus ToxoidmedicineAnimalsHumansAntigens Tumor-Associated CarbohydrateMUC1Vaccines SyntheticThomsen-Friedenreich AntigenChemistryTetanusMucin-1GlycopeptidesToxoidFluorineGeneral ChemistryFlow Cytometrymedicine.diseaseGlycopeptideBiochemistryFemaleConjugateAngewandte Chemie International Edition
researchProduct

Fighting mycobacterial infections by antibiotics, phytochemicals and vaccines.

2011

Buruli ulcer is a neglected disease caused by Mycobacterium ulcerans and represents the world's third most common mycobacterial infection. It produces the polyketide toxins, mycolactones A, B, C and D, which induce apoptosis and necrosis. Clinical symptoms are subcutaneous nodules, papules, plaques and ulcerating oedemae, which can enlarge and destroy nerves and blood vessels and even invade bones by lymphatic or haematogenous spread (osteomyelitis). Patients usually do not suffer from pain or systematic inflammation. Surgery is the treatment of choice, although recurrence is common and wide surgical excisions including healthy tissues result in significant morbidity. Antibiotic therapy wit…

Buruli ulcerNecrosismedicine.drug_classImmunologyAntibioticsBacterial ToxinsInflammationApoptosisQuinolonesMicrobiologyNecrosisBacterial ProteinsmedicineVaccines DNAAnimalsHumansBuruli UlcerbiologyMycobacterium ulceransbusiness.industryOsteomyelitisVaccinationNeglected DiseasesChaperonin 60medicine.diseasebiology.organism_classificationRifamycinsAnti-Bacterial AgentsVaccinationInfectious DiseasesLymphatic systemAminoglycosidesMycobacterium ulceransImmunologyBacterial VaccinesMacrolidesmedicine.symptombusinessPhytotherapyMicrobes and infection
researchProduct

Delivering all in one: Antigen-nanocapsule loaded with dual adjuvant yields superadditive effects by DC-directed T cell stimulation

2018

Therapeutic vaccination is and remains a major challenge, particularly in cancer treatment. In this process, the effective activation of dendritic cells by a combination of distinctly acting adjuvants and an antigen is crucial for success. While most common vaccine formulations lack the efficiency to trigger sufficient T cell responses in a therapeutic tumor treatment, nanovaccines offer unique properties to tackle that challenge. Here, we report the stepwise development of a nanocapsule for vaccination approaches, comprising a shell consisting of antigen and loaded with a superadditive adjuvant combination. In a first initial step, we identified the combination of resiquimod (R848) and mur…

CD4-Positive T-Lymphocytes0301 basic medicineCell SurvivalOvalbuminT-Lymphocytesmedicine.medical_treatmentT cellPharmaceutical ScienceMice Transgenic02 engineering and technologyCD8-Positive T-LymphocytesCancer VaccinesCell Line03 medical and health scienceschemistry.chemical_compoundNanocapsulesAntigenmedicineAnimalsHumansAntigensCytotoxicityAdjuvants PharmaceuticCell ProliferationChemistryImidazolesDextransDendritic CellsDendritic cell021001 nanoscience & nanotechnologyCell biologyMice Inbred C57BL030104 developmental biologymedicine.anatomical_structureCytokinesSpermineResiquimod0210 nano-technologyAcetylmuramyl-Alanyl-IsoglutamineAdjuvantMuramyl dipeptideCD8Journal of Controlled Release
researchProduct

Protein-prime/modified vaccinia virus Ankara vector-boost vaccination overcomes tolerance in high-antigenemic HBV-transgenic mice

2015

Abstract Background Therapeutic vaccination is a novel treatment approach for chronic hepatitis B, but only had limited success so far. We hypothesized that optimized vaccination schemes have increased immunogenicity, and aimed at increasing therapeutic hepatitis B vaccine efficacy. Methods Modified Vaccinia virus Ankara (MVA) expressing hepatitis B virus (HBV) antigens was used to boost protein-prime vaccinations in wildtype and HBV-transgenic (HBVtg) mice. Results Protein-prime/MVA-boost vaccination was able to overcome HBV-specific tolerance in HBVtg mice with low and medium but not with high antigenemia. HBV-specific antibody titers, CD8+ T-cell frequencies and polyfunctionality inverse…

CD4-Positive T-Lymphocytes0301 basic medicineHBsAgHepatitis B vaccineImmunization SecondaryMice TransgenicVaccinia virusCD8-Positive T-Lymphocytesmedicine.disease_cause03 medical and health scienceschemistry.chemical_compoundAntigenNeutralization TestsImmune ToleranceAnimalsMedicineHepatitis B VaccinesHepatitis B e AntigensHepatitis B AntibodiesHepatitis B virusHepatitis B Surface AntigensGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityPublic Health Environmental and Occupational Healthvirus diseasesHepatitis BHepatitis Bmedicine.diseaseAntibodies NeutralizingHepatitis B Core AntigensVirologyMice Inbred C57BLVaccination030104 developmental biologyInfectious DiseaseschemistryImmunologyMolecular MedicineVacciniabusinessVaccine
researchProduct

A Synthetic MUC1 Anticancer Vaccine Containing Mannose Ligands for Targeting Macrophages and Dendritic Cells

2017

A MUC1 anticancer vaccine equipped with covalently linked divalent mannose ligands was found to improve the antigen uptake and presentation by targeting mannose-receptor-positive macrophages and dendritic cells. It induced much stronger specific IgG immune responses in mice than the non-mannosylated reference vaccine. Mannose coupling also led to increased numbers of macrophages, dendritic cells, and CD4+ T cells in the local lymph organs. Comparison of di- and tetravalent mannose ligands revealed an increased binding of the tetravalent version, suggesting that higher valency improves binding to the mannose receptor. The mannose-coupled vaccine and the non-mannosylated reference vaccine ind…

CD4-Positive T-Lymphocytes0301 basic medicinemedicine.medical_treatmentMannoseEnzyme-Linked Immunosorbent AssayReceptors Cell SurfaceLigands010402 general chemistryCancer Vaccines01 natural sciencesBiochemistryDivalentMice03 medical and health scienceschemistry.chemical_compoundImmune systemCancer immunotherapyDrug DiscoverymedicineAnimalsHumansLectins C-TypeGeneral Pharmacology Toxicology and PharmaceuticsMUC1Pharmacologychemistry.chemical_classificationMice Inbred BALB CbiologyChemistryMacrophagesMucin-1Organic ChemistryDendritic CellsMolecular biology0104 chemical sciencesMannose-Binding Lectins030104 developmental biologyLymphatic systemImmunoglobulin GImmunologyMCF-7 Cellsbiology.proteinMolecular MedicineLymph NodesAntibodyMannoseMannose ReceptorMannose receptorProtein BindingChemMedChem
researchProduct

Timing of activation of CD4+ memory cells as a possible marker to establish the efficacy of vaccines against contagious agalactia in sheep

2013

Mycoplasma agalactiae is a major pathogen of sheep and goats in many areas of the world and particularly in Mediterranean countries. It causes contagious agalactia, an infectious disease primarily affecting mammary glands. Many vaccines against the pathogen are currently under development. The aim of the study was to investigate the involvement of T cell-mediated immunity during vaccination and challenge experiments against Mycoplasma agalactiae. A comparison of the antigen-specific expansion of interferon gamma positive T cell memory and naïve subsets was performed between vaccinated and non-vaccinated sheep to identify cellular subsets whose activation was different between protected and …

CD4-Positive T-LymphocytesCellular immunityTime FactorsT cellMycoplasma agalactiaeImmunologyved/biology.organism_classification_rank.speciesSheep DiseasesCD8-Positive T-LymphocytesBiologyLymphocyte ActivationMycoplasma agalactiaeInterferon-gammaT-Lymphocyte SubsetsImmunitymedicineAnimalsMycoplasma InfectionsInterferon gammaMycoplasma agalactiae Cellular immunity IFN-g + cellsPathogenSheep DomesticSheepGeneral Veterinaryved/biologyVaccine efficacyAntibodies BacterialVirologyVaccinationTreatment Outcomemedicine.anatomical_structureImmunoglobulin GBacterial VaccinesImmunologyFemaleImmunologic Memorymedicine.drugVeterinary Immunology and Immunopathology
researchProduct

Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived…

2000

Abstract Dendritic cell (DC) vaccination, albeit still in an early stage, is a promising strategy to induce immunity to cancer. We explored whether DC can expand Ag-specific CD8+ T cells even in far-advanced stage IV melanoma patients. We found that three to five biweekly vaccinations of mature, monocyte-derived DC (three vaccinations of 6 × 106 s.c. followed by two i.v. ones of 6 and 12 × 106, respectively) pulsed with Mage-3A2.1 tumor and influenza matrix A2.1-positive control peptides as well as the recall Ag tetanus toxoid (in three of eight patients) generated in all eight patients Ag-specific effector CD8+ T cells that were detectable in blood directly ex vivo. This is the first time …

CD4-Positive T-LymphocytesCytotoxicity Immunologicmedicine.medical_treatmentInjections SubcutaneousImmunologyImmunization SecondaryEpitopes T-LymphocyteCD8-Positive T-LymphocytesLymphocyte ActivationCancer VaccinesMonocytesViral Matrix ProteinsAntigens NeoplasmTetanus ToxoidImmunology and AllergyMedicineCytotoxic T cellHumansMelanomaCells Culturedbusiness.industryMelanomaToxoidCell DifferentiationDendritic cellDendritic Cellsmedicine.diseaseNeoplasm ProteinsImmunizationImmunologyInjections IntravenousIntercellular Signaling Peptides and ProteinsbusinessPeptidesAdjuvantCD8Ex vivoT-Lymphocytes Cytotoxic
researchProduct

IFN-γ–Producing CD4+ T Cells Promote Generation of Protective Germinal Center–Derived IgM+ B Cell Memory against Salmonella Typhi

2014

Abstract Abs play a significant role in protection against the intracellular bacterium Salmonella Typhi. In this article, we investigated how long-term protective IgM responses can be elicited by a S. Typhi outer-membrane protein C– and F–based subunit vaccine (porins). We found that repeated Ag exposure promoted a CD4+ T cell–dependent germinal center reaction that generated mutated IgM-producing B cells and was accompanied by a strong expansion of IFN-γ–secreting T follicular helper cells. Genetic ablation of individual cytokine receptors revealed that both IFN-γ and IL-17 are required for optimal germinal center reactions and production of porin-specific memory IgM+ B cells. However, mor…

CD4-Positive T-LymphocytesMaleSalmonella VaccinesProtein subunitmedicine.medical_treatmentImmunologyCellBiologySalmonella typhiMicrobiologyInterferon-gammaMice03 medical and health sciences0302 clinical medicinemedicineAnimalsHumansImmunology and AllergyTyphoid FeverReceptorB cell030304 developmental biologyMice KnockoutB-Lymphocytes0303 health sciencesGerminal centerSalmonella typhiGerminal Center3. Good healthVaccinationmedicine.anatomical_structureCytokineImmunoglobulin MbacteriaFemaleImmunologic Memory030215 immunologyThe Journal of Immunology
researchProduct

Impaired immune response to Candida albicans in aged mice

2006

The prevalence of opportunistic fungal infections has increased dramatically among the aged population in recent years. This work investigated the effect of ageing on murine defences against Candida albicans. Aged C57BL/6 mice that were experimentally infected intravenously had a significantly impaired survival and a higher tissue fungal burden compared with young mice. In vitro production of tumour necrosis factor (TNF)-α by macrophages from aged mice in response to yeast cells and hyphae of C. albicans was significantly lower than production by macrophages from young mice. In vitro production of cytokines, such as TNF-α and gamma interferon (IFN-γ), by antigen-stimulated splenocytes from …

CD4-Positive T-LymphocytesMicrobiology (medical)AgingNecrosisBlotting WesternHyphaeMicrobiologyMicrobiologyInterferon-gammaMiceImmune systemAntigenCandida albicansmedicineAnimalsCandida albicansAntibodies FungalCells CulturedbiologyTumor Necrosis Factor-alphaVaccinationCandidiasisGeneral Medicinebiology.organism_classificationAcquired immune systemCorpus albicansMice Inbred C57BLImmunoglobulin GInjections IntravenousImmunologyMacrophages Peritonealbiology.proteinFemaleTumor necrosis factor alphaDisease SusceptibilityFungal Vaccinesmedicine.symptomAntibodySpleenJournal of Medical Microbiology
researchProduct